CN104109667A - 一种核酸片段及其用途 - Google Patents
一种核酸片段及其用途 Download PDFInfo
- Publication number
- CN104109667A CN104109667A CN201410289326.0A CN201410289326A CN104109667A CN 104109667 A CN104109667 A CN 104109667A CN 201410289326 A CN201410289326 A CN 201410289326A CN 104109667 A CN104109667 A CN 104109667A
- Authority
- CN
- China
- Prior art keywords
- estrogen receptor
- nucleic acid
- acid fragment
- aptamer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410289326.0A CN104109667B (zh) | 2014-06-24 | 2014-06-24 | 一种核酸片段及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410289326.0A CN104109667B (zh) | 2014-06-24 | 2014-06-24 | 一种核酸片段及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104109667A true CN104109667A (zh) | 2014-10-22 |
CN104109667B CN104109667B (zh) | 2017-04-05 |
Family
ID=51706656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410289326.0A Active CN104109667B (zh) | 2014-06-24 | 2014-06-24 | 一种核酸片段及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104109667B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105807054A (zh) * | 2015-11-22 | 2016-07-27 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105823879A (zh) * | 2015-11-22 | 2016-08-03 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105823895A (zh) * | 2015-11-22 | 2016-08-03 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN109975097A (zh) * | 2019-04-18 | 2019-07-05 | 山东师范大学 | 一种基于适配体的肿瘤细胞染色探针组合 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101120100A (zh) * | 2005-02-16 | 2008-02-06 | 埃佩多夫阵列技术股份有限公司 | 通过包括转录因子测定的生物标志分析描绘肿瘤的方法和试剂盒 |
WO2013025930A1 (en) * | 2011-08-16 | 2013-02-21 | Research Foundation of State University of New York at Albany | Aptamer modulators of estrogen receptors |
-
2014
- 2014-06-24 CN CN201410289326.0A patent/CN104109667B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101120100A (zh) * | 2005-02-16 | 2008-02-06 | 埃佩多夫阵列技术股份有限公司 | 通过包括转录因子测定的生物标志分析描绘肿瘤的方法和试剂盒 |
WO2013025930A1 (en) * | 2011-08-16 | 2013-02-21 | Research Foundation of State University of New York at Albany | Aptamer modulators of estrogen receptors |
Non-Patent Citations (2)
Title |
---|
XU DAIYING ET AL: "In Search of Novel Drug Target Sites on Estrogen Receptors Using RNA Aptamers", 《NUCLEIC ACID THERAPEUTICS》 * |
XU HE,ET AL: "Using a Sequence of Estrogen Response Elements as a DNA Aptamer for Estrogen Receptors In Vitro", 《NUCLEIC ACID THERAPEUTICS》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105807054A (zh) * | 2015-11-22 | 2016-07-27 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105823879A (zh) * | 2015-11-22 | 2016-08-03 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105823895A (zh) * | 2015-11-22 | 2016-08-03 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105842446A (zh) * | 2015-11-22 | 2016-08-10 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105842445A (zh) * | 2015-11-22 | 2016-08-10 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105842444A (zh) * | 2015-11-22 | 2016-08-10 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN105866412A (zh) * | 2015-11-22 | 2016-08-17 | 李静 | 一种子宫内膜癌特异性检测的试剂盒 |
CN109975097A (zh) * | 2019-04-18 | 2019-07-05 | 山东师范大学 | 一种基于适配体的肿瘤细胞染色探针组合 |
Also Published As
Publication number | Publication date |
---|---|
CN104109667B (zh) | 2017-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cheng et al. | FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation | |
Wang et al. | Long non-coding RNA BLACAT1 promotes cell proliferation, migration and invasion in cervical cancer through activation of Wnt/β-catenin signaling pathway. | |
Ye et al. | Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition | |
Tian et al. | Differential expression of G-protein-coupled estrogen receptor-30 in human myometrial and uterine leiomyoma smooth muscle | |
Huang et al. | Knockdown of long noncoding RNA GHET1 inhibits cell activation of gastric cancer | |
Cheng et al. | E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness | |
Zhu et al. | Hepatitis B virus X protein driven alpha fetoprotein expression to promote malignant behaviors of normal liver cells and hepatoma cells | |
Lanigan et al. | Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro | |
CN104109667A (zh) | 一种核酸片段及其用途 | |
Voudouri et al. | IGF-I/EGF and E2 signaling crosstalk through IGF-IR conduit point affects breast cancer cell adhesion | |
Wu et al. | The malignancy of miR-18a in human glioblastoma via directly targeting CBX7 | |
Guo et al. | Overexpression of SCUBE2 inhibits proliferation, migration, and invasion in glioma cells | |
Zhuandi et al. | FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ERβ in normal ovarian tissues | |
Shi et al. | Expression and prognostic role of orphan receptor GPR110 in glioma | |
Wang et al. | Effect of shRNA mediated down-regulation of Annexin A2 on biological behavior of human lung adencarcinoma cells A549 | |
Singsuksawat et al. | Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells | |
Wang et al. | KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth | |
Wu et al. | Hsa_circ_0043278 functions as competitive endogenous RNA to enhance glioblastoma multiforme progression by sponging miR-638 | |
Ding et al. | GOLM1 silencing inhibits the proliferation and motility of human glioblastoma cells via the Wnt/β-catenin signaling pathway | |
He et al. | Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells | |
Hu et al. | Vimentin binds to a novel tumor suppressor protein, GSPT1-238aa, encoded by circGSPT1 with a selective encoding priority to halt autophagy in gastric carcinoma | |
Ou et al. | Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer | |
Qu et al. | Osterix promotes the migration and angiogenesis of breast cancer by upregulation of S100A4 expression | |
Yamaga et al. | Systemic identification of estrogen-regulated genes in breast cancer cells through cap analysis of gene expression mapping | |
Luo et al. | MiR-22-3p regulates the proliferation and invasion of Wilms' tumor cells by targeting AKT3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SICHUAN HELI BIOLOGY PHARMACEUTICAL CO., LTD. Effective date: 20150511 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150511 Address after: Zi Chuang street Qingyang District Chengdu 611130 Sichuan province No. 42 unit 3 No. 7 Applicant after: Ye Shangmian Address before: Zi Chuang street in Chengdu City, Sichuan province 611130 42 unit 3, No. 7 Applicant before: Ye Shangmian Applicant before: SICHUAN HELI BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180314 Address after: And the center of Sichuan province in 610000 Haitang No. 2039 Chengdu Tianfu Tianfu Avenue South (Tianfu hit off 16 floor No. 1609) Patentee after: Chengdu Jie Mi Card Technology Co. Ltd. Address before: Zi Chuang street Qingyang District Chengdu 611130 Sichuan province No. 42 unit 3 No. 7 Patentee before: Ye Shangmian |